Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6CS1B
|
|||
| Drug Name |
AAV-GAD
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 2 | [1] | |
| Company |
MeiraGTx
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glutamic acid decarboxylase 1 (GAD1) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00643890) Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007 Jun 23;369(9579):2097-105. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.